Coherus Will Not Alert Filing Of Pegfilgrastim On-Body

Approval Or Launch Will Trigger Notification To Market

 
• By Dean Rudge

Going toe-to-toe with Amgen on its Neulasta Onpro on-body injector device is a key strategic goal for Coherus BioSciences, although news will be kept concealed until the company’s proposed biosimilar is approved or launched.

Growth Strategy
Coherus is looking to drive revenue growth after a fall in 2022 • Source: Shutterstock

More from Biosimilars

More from Products